Harry Potter: Hogwarts Mystery Brings New Choices, Challenges and Couture with February Sidequest, the Celestial Ball
8.2.2019 14:00:00 EET | Business Wire | Press release
Jam City:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190208005009/en/
Harry Potter: Hogwarts Mystery Celestial Ball (Graphic: Business Wire)
|
Who: |
Jam City, a Los Angeles-based mobile games studio, in partnership with Warner Bros. Interactive Entertainment’s Portkey Games, a label dedicated to creating new Wizarding World mobile and videogame experiences that place the player at the center of their own adventure, inspired by J.K. Rowling’s original stories. |
||
|
What: |
This February, in the mobile game, Harry Potter: Hogwarts Mystery, Hogwarts is abuzz with the social event of the season – the Celestial Ball! In this special adventure, fourth-year players and above can participate in the after-class planning and preparations for this first formal dance. Maneuvering a host of choices and social situations, players will partner with their peers in an effort to make the event a resounding, resplendent success! | ||
| In the quest, players will help other Hogwarts classmates with their own Celestial Ball aspirations. For example, the popular Hufflepuff Penny hopes to head the Decorating Committee, but the devious duo of Merula and Ismelda have set their sights on sabotage. Meanwhile, introverted classmates like Rowan require makeover tips and pep talks, to put their best foot forward at the dance. | |||
| Before the grand event, players can visit the Great Hall to mingle with classmates like Tulip, Barnaby, Rowan, Ben, Merula, Penny and others, and choose a friend to invite to the ball. With the sidequest all but complete, players will be able to choose their own outfit for the ball from a selection of looks curated by fashion-forward Ravenclaw, Andre. | |||
|
Quote: |
“Life at Hogwarts is filled with classes, studies, extra-curricular activities – but also social events and celebrations,” said Michael Brozman, Sr. Director of Product at Jam City. “We’re thrilled to introduce the Celestial Ball time-limited sidequest this February, giving players the opportunity to explore the excitement, choices and camaraderie of a Hogwarts school dance.” | ||
|
Background: |
Harry Potter: Hogwarts Mystery is the first mobile game where players can create their own character and experience life as a Hogwarts student. In the narrative adventure with RPG elements, players will create a personalized student avatar, attend classes, learn magical skills, and form friendships or rivalries with other students. In the game, players make pivotal decisions that influence their character’s story arc at Hogwarts. The game features a new encounter system where player decisions and actions impact their quests, allowing Harry Potter fans to create their own legacy as a witch or wizard. |
||
For more details on Harry Potter: Hogwarts Mystery and to connect with other fans, visit www.facebook.com/HPHogwartsMystery/, www.twitter.com/HogwartsMystery, and for more information visit www.HarryPotterHogwartsMystery.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190208005009/en/
Contact information
Media:
Jam City
Sarah Ross, 310-924-1404
sarahr@jamcity.com
or
Dana
Whitney, 415-359-7006
dwhitney@jamcity.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom